Pulmonary Aspergillosis clinical trials

Explore recruiting pulmonary aspergillosis clinical trials.

Recruiting pulmonary aspergillosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pulmonary Aspergillosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, monocentric, prospective, nonrandomized, open-label, experimental study to evaluate efficacy and safety of intrabronchial instillation of liposomal Amphotericin B in patients with simple pulmonary aspergilloma.

Latvia

Therapeutic exploratory (Phase II) EU CTIS Study details

iMagIng pulmonaRy Aspergillosis using Gallium-68-dEferoxamine (MIRAGE)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

CPAAARI-Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole alone in non- or mildly- immunocompromised patients with Chronic Pulmonary Aspergillosis: a prospective, randomized, single blind study, (single aspergilloma excluded).

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis (OPERA-T study)

Spain, Austria, Belgium, Italy, Greece, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 2, multicentre, open-label, single arm study to evaluate the effectiveness and safety of rezafungin (as acetate) in the treatment of chronic pulmonary aspergillosis (CPA) in patients with limited treatment options

Hungary, Belgium, Austria, Germany, Netherlands, Italy +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Nebulised lIposomal aMphotericin B in chronic pUlmonary aSpergillosis: a deposition study

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

Pulmonary Aspergillosis trials by city

Pulmonary Aspergillosis in Toronto Pulmonary Aspergillosis in Vancouver Pulmonary Aspergillosis in Montreal Pulmonary Aspergillosis in Calgary Pulmonary Aspergillosis in Edmonton Pulmonary Aspergillosis in Ottawa Pulmonary Aspergillosis in Winnipeg Pulmonary Aspergillosis in Quebec City Pulmonary Aspergillosis in Hamilton Pulmonary Aspergillosis in Kitchener Pulmonary Aspergillosis in London Pulmonary Aspergillosis in Halifax Pulmonary Aspergillosis in New York Pulmonary Aspergillosis in Los Angeles Pulmonary Aspergillosis in Chicago Pulmonary Aspergillosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease